Inclusion Criteria:

- Age ≥18 years

- ECOG performance score of 0-3

- Expected survival of >12 weeks

- Subjects with advanced HCC or locally advanced, unresectable HCC

- Elevated LFTs (including at least one of the following: TBili >1.5 times the upper
limit of normal; serum AST >2.5 times the upper limit of normal

- HCC diagnosed/defined based on either biopsy, or by suggestive radiologic imaging
according to the AASLD guidelines (arterial enhancement with venous washout) or an
AFP >200 ng/ml

- Subjects must have measurable disease that can be accurately measured in at least one
dimension (with at least >20mm diameter in the longest dimension by conventional
imaging or >10 mm by helical CT)

- Elevated liver enzymes that are either due to underlying liver disease and/or tumor
which is not amenable to stenting after discussion with interventional GI and/or IR

- Subjects must demonstrate an ability to understand the consent process and
willingness to sign a written informed consent form

- Subjects must agree to use birth control pills or other active contraception during
active study treatment

Exclusion Criteria:

- Pregnant women or women currently breastfeeding will be excluded from this study
because the effects of silybin on pregnant women and/or nursing infants are not known

- Subjects must have < grade 4 hepatic toxicity

- Known brain metastases because of poor prognosis and as patients with brain
metastases often develop neurological dysfunction that may confound evaluation of
neurologic and other adverse side effects

- History of allergic reactions to the study medication

- Uncontrolled concurrent illness including, but not limited to: ongoing active
infection (including SBP), symptomatic congestive heart failure, unstable angina,
active cardiac arrhythmia, or psychiatric illness that would limit compliance with
study requirements